---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-25-000078"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:42:32.819344+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Salarius amends Decoy merger: removes $2M threshold, changes conversion price adjustment

## Summary
- Fourth Amendment dated July 29, 2025 removes $2M threshold for 'subsequent financing' triggering conversion adjustment.
- Conversion price adjustment changes from weighted average to actual per share offering price in subsequent financings.
- One-year limitation on conversion ratio adjustments eliminated; adjustments apply until stockholder approval and Nasdaq listing standards met.
- Amendments intended to induce holders of Decoy convertible/non-convertible notes to consent and convert.

## SEC filing metadata
- accession: 0001615219-25-000078
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000078/0001615219-25-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000078/flks-20250729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-25-000078
- JSON: https://secwatch.observer/filing/0001615219-25-000078.json
- Plain text: https://secwatch.observer/filing/0001615219-25-000078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.